Physician profile
Kofi K Quist
NPI 1932428836
$5,247.63
in general payments reported to CMS, 2019-2025
35 companies · $986 in 2025
The $986 reported for 2025 was more than what 89% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $522 · 2021: $471 · 2022: $673 · 2023: $594 · 2024: $1,537 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,116.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $731.41 | 2019-2024 | |
| Ucb, INC. | $628.52 | 2020-2025 | Nayzilam, Briviact |
| Pfizer INC. | $621.74 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $515.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $470.25 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $309.78 | 2022-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $290.43 | 2022-2025 | Apokyn, Apokyn |
| Catalyst Pharmaceuticals, INC. | $241.70 | 2023-2024 | Fycompa |
| Abbvie INC. | $165.86 | 2021-2025 | |
| Csl Behring | $160.46 | 2019-2024 | Hizentra |
| Sk Life Science, INC. | $141.83 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $107.21 | 2025 | |
| Neuropace, INC. | $92.87 | 2024 | |
| Acadia Pharmaceuticals INC | $82.13 | 2021-2025 | Nuplazid |
| Harmony Biosciences LLC | $78.29 | 2023-2024 | Wakix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $72.02 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $70.88 | 2025 | |
| Aquestive Therapeutics, INC. | $60.49 | 2019-2024 | |
| Biocodex, INC. | $49.69 | 2023-2024 | Diacomit |
| Alexion Pharmaceuticals, INC. | $42.11 | 2025 | Ultomiris |
| Scilex Pharmaceuticals INC. | $31.89 | 2024 | |
| Genentech USA, INC. | $30.80 | 2022-2025 | Ocrevus |
| Biogen, INC. | $29.66 | 2025 | Vumerity, Avonex, Tysabri |
| Janssen Pharmaceuticals, INC | $25.91 | 2022 | |
| Lilly USA, LLC | $25.64 | 2024 | Emgality |
| Merz North America, INC. | $20.68 | 2020 | |
| Livanova USA, INC. | $20.16 | 2019 | |
| Merz Pharmaceuticals, LLC | $19.63 | 2021 | |
| Springworks Therapeutics, INC. | $19.14 | 2025 | Gomekli |
| Aucta Pharmaceuticals, INC. | $17.85 | 2024 | Motpoly Xr |
| Azurity Pharmaceuticals, INC. | $17.45 | 2024 | Zonisade |
| Allergan, INC. | $15.01 | 2020 | |
| Amneal Pharmaceuticals LLC | $14.45 | 2023 | Rytary |
| Sanofi-Aventis U.S. LLC | $13.97 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kofi Quist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.